ECSP23019295A - Composiciones de vacunas multivalentes y usos de las mismas - Google Patents

Composiciones de vacunas multivalentes y usos de las mismas

Info

Publication number
ECSP23019295A
ECSP23019295A ECSENADI202319295A ECDI202319295A ECSP23019295A EC SP23019295 A ECSP23019295 A EC SP23019295A EC SENADI202319295 A ECSENADI202319295 A EC SENADI202319295A EC DI202319295 A ECDI202319295 A EC DI202319295A EC SP23019295 A ECSP23019295 A EC SP23019295A
Authority
EC
Ecuador
Prior art keywords
compositions
expec
methods
multivalent vaccines
coli
Prior art date
Application number
ECSENADI202319295A
Other languages
English (en)
Inventor
Kellen Fae
Michal Sarnecki
Bart Spiessens
Jeroen Geurtsen
Frank Struyf
Jan Poolman
Darren Abbanat
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of ECSP23019295A publication Critical patent/ECSP23019295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se describen composiciones y métodos para inducir una respuesta inmunitaria contra la Escherichia coli patógena extraintestinal (ExPEC) para proporcionar de este modo una protección inmunitaria contra las enfermedades asociadas a la ExPEC. En particular, se describen composiciones y métodos para utilizar conjugados del polisacárido de antígeno O75 de E. coli unidos de manera covalente a una proteína portadora para la prevención de la enfermedad invasiva por ExPEC.
ECSENADI202319295A 2020-09-17 2023-03-17 Composiciones de vacunas multivalentes y usos de las mismas ECSP23019295A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079734P 2020-09-17 2020-09-17
EP21154782 2021-02-02
US202163191471P 2021-05-21 2021-05-21

Publications (1)

Publication Number Publication Date
ECSP23019295A true ECSP23019295A (es) 2023-04-28

Family

ID=77801756

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202319295A ECSP23019295A (es) 2020-09-17 2023-03-17 Composiciones de vacunas multivalentes y usos de las mismas

Country Status (19)

Country Link
US (2) US12233118B2 (es)
EP (1) EP4213870A1 (es)
JP (2) JP7481585B2 (es)
KR (1) KR20230043157A (es)
CN (3) CN119454928A (es)
AU (1) AU2021342797B2 (es)
BR (1) BR112023004819A2 (es)
CA (1) CA3190820C (es)
CL (1) CL2023000740A1 (es)
CO (1) CO2023002114A2 (es)
EC (1) ECSP23019295A (es)
IL (2) IL301248B2 (es)
JO (1) JOP20230057A1 (es)
MX (1) MX2023003169A (es)
PE (1) PE20231385A1 (es)
PH (1) PH12023550020A1 (es)
TW (1) TW202227128A (es)
UY (1) UY39428A (es)
WO (1) WO2022058945A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202192392A1 (ru) 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AR131046A1 (es) * 2022-11-15 2025-02-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y sus usos
WO2024146325A1 (zh) * 2023-01-06 2024-07-11 中国人民解放军军事科学院军事医学研究院 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用
GB202302579D0 (en) * 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024186262A1 (en) * 2023-03-03 2024-09-12 Agency For Science, Technology And Research Use of o-antigens for treating bacterial infections
EP4478050A1 (en) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Method for quantifying bound acetate in glycoconjugates

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B1 (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
EP1385541B1 (en) 2000-04-13 2008-06-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
CA2406229C (en) 2000-04-18 2010-09-07 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
CN1324134C (zh) 2003-12-22 2007-07-04 南开大学 对大肠杆菌o81型的o－抗原特异的核苷酸
JP5010464B2 (ja) 2004-03-30 2012-08-29 エヌエスジーン・アクティーゼルスカブ 成長因子、ＮｓＧ３３の治療上の使用
DK1888761T3 (da) 2005-05-11 2010-11-01 Eth Zuerich Rekombinante N-glycosylerede proteiner fra prokaryote celler
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
WO2009089396A2 (en) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
LT2257307T (lt) 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
WO2010125565A2 (en) 2009-04-27 2010-11-04 Hadasit Medical Research Services And Development Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
CN102724997B (zh) 2009-11-19 2016-09-21 格林考瓦因有限公司 在原核细胞中产生免疫原性多糖的生物合成系统
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
AR084158A1 (es) 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
CA2847621A1 (en) 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
HUE049531T2 (hu) 2012-08-16 2020-10-28 Pfizer Glikokonjugációs eljárások és kompozíciók
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2720040T3 (es) 2012-10-12 2019-07-17 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
US20150273043A1 (en) 2012-11-07 2015-10-01 Glycovaxyn Ag Production of recombinant vaccine in e.coli by enzymatic conjugation
KR101980989B1 (ko) 2012-12-20 2019-05-21 화이자 인코포레이티드 당접합 방법
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Ｃｒｍ１９７に関する方法及び組成物
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
CA2926523C (en) 2013-10-11 2023-09-26 Glycovaxyn Ag Methods of host cell modification
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
JP2016540764A (ja) 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
RU2724530C2 (ru) 2014-02-06 2020-06-23 Экс4 Фамасьютиклз (Остриэ) ГмбХ Выделенное антитело (варианты), способ получения антитела, выделенная нуклеиновая кислота, экспрессионная кассета (варианты), плазмида (варианты), клетка-хозяин, фармацевтический препарат, набор, способ лечения больного, подверженного риску или страдающего от инфекции e.coli, и способ диагностики определения инфекций e.coli
JP6276427B2 (ja) 2014-02-24 2018-02-07 グリコヴァキシン アーゲー 新規の多糖及びその使用
HUE049806T2 (hu) 2014-04-17 2020-10-28 Glaxosmithkline Biologicals Sa Módosított gazdasejtek és alkalmazásaik
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
DK3240895T3 (da) 2014-12-30 2022-04-11 Glaxosmithkline Biologicals Sa Sammensætninger og fremgangsmåder til proteinglykosylering
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EA202192392A1 (ru) * 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
CN117222427A (zh) * 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产

Also Published As

Publication number Publication date
AU2021342797A1 (en) 2023-02-16
US20220088165A1 (en) 2022-03-24
AU2021342797B2 (en) 2024-02-08
IL301248A (en) 2023-05-01
CO2023002114A2 (es) 2023-03-07
JOP20230057A1 (ar) 2023-03-16
CN115803087A (zh) 2023-03-14
IL301248B1 (en) 2023-12-01
CN119454927A (zh) 2025-02-18
IL301248B2 (en) 2024-04-01
PH12023550020A1 (en) 2024-03-11
JP7481585B2 (ja) 2024-05-10
KR20230043157A (ko) 2023-03-30
CN115803087B (zh) 2024-12-06
UY39428A (es) 2022-03-31
CA3190820C (en) 2024-11-19
WO2022058945A1 (en) 2022-03-24
EP4213870A1 (en) 2023-07-26
JP2023539943A (ja) 2023-09-20
CA3190820A1 (en) 2022-03-24
TW202227128A (zh) 2022-07-16
IL308201A (en) 2024-01-01
US12233118B2 (en) 2025-02-25
BR112023004819A2 (pt) 2023-04-18
JP2024099716A (ja) 2024-07-25
CL2023000740A1 (es) 2023-09-29
PE20231385A1 (es) 2023-09-12
MX2023003169A (es) 2023-03-27
CN119454928A (zh) 2025-02-18
US20250222088A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
ECSP23019295A (es) Composiciones de vacunas multivalentes y usos de las mismas
MX2021011418A (es) Metodos de produccion de bioconjugados de polisacaridos de e. coli o- antigeno, sus composiciones y metodos de utilizacion.
NI202000040A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
BR112018003469A2 (pt) composição, método para induzir uma resposta imune a e. coli patogênica extraintestinal, e, processo para produzir uma composição.
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
AR100859A1 (es) Polisacáridos y sus usos
MX2017014127A (es) Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
NI202100050A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
CO2021001926A2 (es) Composiciones de escherichia coli y métodos de estas
Bacelo et al. Xanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis
MX2016002386A (es) Vacuna bacteriana y metodos para la fabricacion de la misma.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX2023007228A (es) Constructo de arn.
AR079375A1 (es) Soluciones de rehidratacion oral que comprenden dextrosa. metodo de preparacion.
ECSP22031077A (es) Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación
AR123545A1 (es) Composiciones de vacunas multivalentes y usos de las mismas
AR105793A1 (es) Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal
MX2022001937A (es) Composicion inmunogenica.
MX2021015155A (es) Polisacaridos de ramnosa.
WO2024107729A3 (en) Multivalent vaccine compositions and uses thereof
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
Bacelo et al. Research Article Xanthan Gum as an Adjuvant in a Subunit Vaccine Preparation against Leptospirosis
AR104514A1 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos